EPO vs LGD-4033
A side-by-side research comparison of EPO and LGD-4033 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | EPO | LGD-4033 |
|---|---|---|
| Full name | Erythropoietin (EPO) | Ligandrol (LGD-4033) |
| Category | Muscle Growth | Muscle Growth |
| Status | FDA-approved drug (prescription) | Investigational |
| Mechanism | Binds erythropoietin receptors on bone marrow progenitor cells, stimulating proliferation and maturation of red blood cells. More red cells raise oxygen-carrying capacity, but also thicken the blood. | Selectively binds androgen receptors in muscle and bone, activating anabolic gene transcription while avoiding prostate activity. |
| Molecular weight | ~34 kDa (glycosylated) | 338.25 Da |
| Half-life | ~4-13 hours (varies by formulation) | ~24-36 hours |
| Bioavailability | Subcutaneous or intravenous injection | ~90% oral |
| Typical dose | Prescription-only, condition-specific | 5-10 mg |
| Frequency | Per medical protocol | Once daily |
| Route | Subcutaneous or IV injection | Oral |
EPO reported benefits
- Increases red blood cell production
- Treats anemia (medical use)
- Raises oxygen-carrying capacity
LGD-4033 reported benefits
- Significant lean mass gains
- Bone density improvement
- Oral convenience
- Selective tissue activity
Related comparisons
Research and educational reference only. Not medical advice.